Call Us for Support
+91 9654860915
Google Reviews
4.8
Call Us for Support
+91 9654860915
Sourced directly from the authorized manufacturer network to ensure authenticity and quality.
Ready to proceed? Start a request for Suraxavir Marboxil on our secure patient portal to submit your prescription, upload documents and track your approval status.
Supplied with complete CDSCO-approved import and customs documentation, including Form 12A & 12B, CDEC, GST Bill of Entry, Commercial Invoice, and Packing List.
Manufacturer / Innovator:
China
Regulatory Approval:
Your Trustworthy Partner For Named Patient Program
Over a decade of trusted expertise in Named Patient Access to innovative and life-saving medicines.
100% CDSCO-compliant processes ensuring safe, ethical, and responsible medicine access.
Medicines sourced from authorized manufacturers with full batch traceability.
EU-GDP compliant warehousing for secure, quality-controlled global distribution.
Temperature-controlled logistics ensuring safe, reliable, and timely medicine delivery.
Suraxavir marboxil is a one-dose oral antiviral for flu, developed in China by Jiangxi Qingfeng Pharmaceutical together with Ginkgo Pharmaceutical. It is sold there as 伊速达® (Yisuda), and the marketing licence is held by Jiangxi Kerui Pharmaceutical Co., Ltd. A whole course is a single dose taken on one day.
China's National Medical Products Administration (NMPA) approved it in March 2025 for:
It is a prescription infection medicine and should be used only on a doctor's advice.
The tablet contains a "prodrug" that the body turns into its active form, suraxavir. This blocks the PA endonuclease, a part of the flu virus's copying machinery that cuts a cap off the patient's own genetic messages so the virus can start making copies of itself. With that step blocked, the virus cannot multiply. The active form stays in the body for several days (a half-life of roughly 58 to 76 hours in volunteers), which is why one dose is enough.
The phase 3 trial, published in Nature Medicine in 2025, included 591 otherwise healthy outpatients aged 5 to 65 at 46 centres in China, all treated within 2 days of their first flu symptoms. A single 40 mg dose eased flu symptoms in a median of 42 hours compared with 63 hours on placebo. One day after the dose, the amount of virus had dropped much faster than with placebo. An earlier phase 2 trial, in which almost all patients had influenza B, also showed faster recovery (median 46 to 50 hours compared with 82 hours on placebo).
Your doctor will confirm whether it suits you. Like all flu antivirals, it works best when started early.
This information is not a treatment plan. For personalized medical advice, consult your doctor and refer to the full prescribing information.
Side effects: in the phase 3 trial, 28.4% of people who took suraxavir marboxil reported a side effect of any kind, compared with 23.3% on placebo, and most were mild or moderate. Diarrhoea was the most often reported side effect in the phase 2 trial (7.6%).
It treats the flu virus only. A cough or fever that gets worse, or breathlessness, can mean a chest infection that needs separate care. Safety in pregnancy and breastfeeding has not been established in the published data, so discuss this with your doctor first.
Step 1 – Search & request your medicine: The patient or treating doctor submits a request with basic details to initiate the access process.
Step 2 – Verification & eligibility review: The team verifies availability and reviews eligibility against regulatory and clinical requirements to ensure a compliant pathway.
Step 3 – Receive quote & delivery timeline: A transparent quotation is shared, covering medicine cost, logistics, and a clear delivery timeline.
Step 4 – Regulatory approval process: Assistance is provided to secure the approvals and documentation required for legal cross-border access.
Step 5 – Temperature-controlled import & handling: The medicine is sourced and transported under strict GDP-compliant conditions to maintain product integrity.
Step 6 – Secure delivery: The medicine is delivered to the patient or treating hospital, with updates provided at each stage.
Note: From request to delivery, every step is designed to ensure your treatment reaches you safely, compliantly, and without unnecessary delays.
The tablets can be imported only in the patient's name, by the patient or a government hospital, in line with India's import regulations for unapproved medicines. You will need:
Once we have received and checked a valid prescription and, where needed, an import permit.
No. It is approved only in China. It has no CDSCO approval, it is not sold in Indian pharmacies, and the US FDA and European Medicines Agency have not approved it either.
Patients can still get it legally through the Named Patient Program (NPP), which allows a medicine not registered in India to be imported for one specific patient on a prescription. Because the dose must be taken within 48 hours of the first symptoms, ask your doctor whether the import timeline still fits. For other imported antiviral tablets, see our pages on Simnotrelvir and Livtencity.
It can be made available to patients, doctors, and hospitals across major cities in India, including Gurgaon, Delhi, Bangalore, Mumbai, Navi Mumbai, Thane, Hyderabad, Mysore, Kerala, Chennai, Coimbatore, Madurai, Kolkata, Ahmedabad, Surat, Vadodara, Pune, Nagpur, Nashik, Jaipur, Udaipur, Lucknow, Kanpur, Gorakhpur, Chandigarh, Mohali, Faridabad, Noida, Ghaziabad, Kochi, Trivandrum, Kozhikode, Thrissur, Kannur, Mangalore, Bhubaneswar, Patna, Ranchi, Raipur, Guwahati, Visakhapatnam, Vijayawada, Goa, Jammu, Srinagar, Dehradun, Bhopal, Indore, Ludhiana, Amritsar, and others — and can facilitate delivery to the patient's treating hospital. Orders are confirmed only after receipt of a valid doctor's prescription and an import permit, where applicable.
NamedPatientProgram.com (NPP) sources this medicine through the manufacturer's authorised supply channels in China and arranges supply to patients, doctors, and hospitals under applicable legal provisions. The tablets stay in their sealed original pack and are stored as directed on the pack during transit. A full course is just two 20 mg tablets, taken together once. All prescriptions are dispensed and checked by registered pharmacists and dispatched from New Delhi, India, after legal requirements are fulfilled.
For the current cost in India and availability, contact NPP via WhatsApp at +91 98104 69557 | Toll-Free: 1800-1200-365 or email info@namedpatientprogram.com.
Patients across India can access this medicine through regulated import pathways, with delivery arranged to the patient or the treating clinic on a valid doctor's prescription.
Patients near our New Delhi dispatch point have the shortest delivery time, which helps with a medicine taken early in the illness.
Doctors in Mumbai can send the prescription, flu test and body weight together so we can check everything in one go.
The single-dose pack can be delivered to the patient's home or clinic in Bangalore once the documents are cleared.
We confirm the quote and expected delivery date first, so the doctor can decide if the timing still works.
Physicians in Hyderabad can request it for a named patient aged 12 or over with uncomplicated flu.
Deliveries to Kolkata and the eastern states are routed to arrive as quickly as the import process allows.
Patients in Pune can use the same documented import route, with updates at each stage.
The treating doctor can share the prescription and test report with us to start the request.
Serves patients from Punjab, Haryana and Himachal Pradesh, with delivery to the patient or the treating hospital.
Families in Rajasthan can receive the pack at home, provided the import is in the patient's own name.
We arrange delivery for patients treated at public and private hospitals across Uttar Pradesh.
Patients across Kerala can have the tablets delivered to their home or hospital in Kochi and nearby cities.
Access can also be coordinated for patients in other Indian cities, subject to a valid prescription and regulatory requirements.
Written By
Nitin GoswamiDeputy Manager – Content & Social Media, Ikris Pharma Network
Sources: NMPA • CDSCO
Last Updated: 19 October 2026
Our specialists are here to guide you through every step of the medicine access process.
Mail Us At:
info@namedpatientprogram.comContact Us:
+91 9654860915Send us a message
